Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin / 대한간학회지
The Korean Journal of Hepatology
;
: 183-188, 2011.
Article
in English
| WPRIM
| ID: wpr-35140
ABSTRACT
BACKGROUND/AIMS:
The reappearance rates of hepatitis C virus (HCV) RNA after a sustained virological response (SVR) have been reported to be 1-2%. We investigated the reappearance rate of HCV RNA after SVR in chronic hepatitis C (CHC) patients treated with pegylated interferon (PEG-IFN) and ribavirin.METHODS:
In total, 292 CHC patients who achieved an SVR after PEG-IFN and ribavirin treatment were included. They were treated with subcutaneous injections of either PEG-IFN-alpha 2a or 2b plus ribavirin orally. Liver function tests and qualitative HCV RNA assays were performed every 6 months during the follow-up period after an SVR.RESULTS:
Among the 292 patients, 224 (genotype 1, 92; genotype non-1, 132) were followed up for more than 6 months after SVR. These 224 patients were aged 48.1+/-11.5 years (mean+/-SD), and 129 of them were male. The median follow-up duration was 18 months (range 6-60 months). The reappearance rate of HCV RNA during follow-up was 0%. Two patients who achieved an SVR developed hepatocellular carcinoma during the follow-up period.CONCLUSIONS:
An SVR was maintained in all CHC patients treated with PEG-IFN plus ribavirin during a median follow-up of 18 months. However, a screening test for hepatocellular carcinoma is needed for patients with an SVR.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Antiviral Agents
/
Polyethylene Glycols
/
Ribavirin
/
Recombinant Proteins
/
RNA, Viral
/
Follow-Up Studies
/
Interferon-alpha
/
Hepatitis C, Chronic
/
Drug Therapy, Combination
/
Genotype
Type of study:
Observational study
/
Prognostic study
/
Qualitative research
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
English
Journal:
The Korean Journal of Hepatology
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS